tirzepatide for obstructive sleep apnea Breakthrough Treatment Apnea: FDA Approves Zepbound ( Tirzepatide) Zepbound - Available at Chicago

Kolotkin RL, Gabriel Smolarz B, Meincke HH, Fujioka K

The intervention consisted of diet and exercise counseling and randomization to intravenous infusion of bimagrumab (10 mg/kg up to 1200 mg in 5% dextrose solution) or placebo (5% dextrose solution) treatment every 4 weeks for 48 weeks

This meta-analysis deliberately set that indication aside and asked a different question: once spasticity is accounted for, does the same medicine also move the needle on bladder function, sleep disruption, spasm quality, and gait

The medication could have certain direct effects on relieving pain

Time your doses strategically Inject on the same day each week